Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1Glioblastoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Bronchiolitis Obliterans Syndrome 1Brain Neoplasms 1

Interventions

Gemcitabine 15Cisplatin 9Paclitaxel 6Nivolumab 5Fluorouracil 4Carboplatin 4atezolizumab 3Sunitinib 3Specimen Handling 3Radiotherapy 3Doxorubicin 3pegfilgrastim 2eribulin 2cabozantinib 2avelumab 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Ifosfamide 2Docetaxel 2CTLA-4 Antigen 2Biopsy 2vinflunine 1vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1rubitecan 1romidepsin 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urethral Neoplasms × lonafarnib × Clear all
NCT00006351 2012-09-24

SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
34 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡